Blockade of latent inhibition following pharmacological increase or decrease of GABA(A) transmission

Pharmacology Biochemistry and Behavior

Volumn 66, Issue 4, 2000, Pages 893-901

  Lacroix, Laurent ^a   Spinelli, Simona ^a   Broersen, Laus M ^a   Feldon, Joram ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Attention; Chlordiazepoxide; GABA(A) receptors; Latent inhibition; Pentylenetetrazole; Rat; Ro15 4513

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CHLORDIAZEPOXIDE; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; CONDITIONING; CONTROLLED STUDY; CONVULSION; GABAERGIC SYSTEM; LATENT INHIBITION; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AFFINITY LABELS; ANIMALS; AZIDES; BENZODIAZEPINES; CHLORDIAZEPOXIDE; CONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA MODULATORS; MALE; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; RECEPTORS, GABA-A; STARTLE REACTION;

EID: 0033869722     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00269-0     Document Type: Article

References (78)

1. Allan A.M., Harris R.A. Gamma-aminobutyric acid agonists and antagonists alter chloride flux across brain membranes. Mol. Pharmacol. 29:1986;497-505.
2. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176:1988;578-606.
3. Baruch I., Hemsley D.R., Gray J.A. Latent inhibition and 'psychotic proneness' in normal subjects. Person. Indiv. Diff. 9:1988;777-783.
4. Benes F.M. The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. J. Psychiatr. Res. 31:1997;257-275.
5. Brodie M.J., McKee P.J. Vigabatrin and psychosis. Lancet. 335:1990;1279.
6. Cannizzaro G., Flugy A., Cannizzaro C., Gagliano M., Sabatino M. Effects of desipramine and alprazolam in the forced swim test in rats after long lasting termination of chronic exposure to picrotoxin and pentylenetetrazol. Eur. Neuropsychopharmacol. 3:1993;477-484.
7. Carey M.P., Fry J.P. A behavioural and pharmacological evaluation of the discriminative stimulus induced by pentylenetetrazole in the pig. Psychopharmacology (Berlin). 111:1993;244-250.
8. Cole B.J., Hillmann M. Effects of benzodiazepine receptor ligands on the performance of an operant delayed matching to position task in rats. Opposite effects of FG 7142 and lorazepam Psychopharmacology (Berlin). 115:1994;350-357.
9. Cole S.O. Combined effects of chlordiazepoxide treatment and food deprivation on concurrent measures of feeding and activity. Pharmacol. Biochem. Behav. 18:1983;369-372.
10. Cooper S.J. GABA and endorphin mechanisms in relation to the effects of benzodiazepines on feeding and drinking. Prog. Neuropsychopharmacol. Biol. Psychiatry. 7:1983;495-503.
11. Cooper S.J., Estall L.B. Behavioral pharmacology of food, water and salt intake in relation to drug actions at benzodiazepine receptors. Neurosci. Biobehav. Rev. 9:1985;5-19.
12. Corda M.G., Giorgi O., Longoni B., Orlandi M., Biggio G. Decrease in the function of the aminobutyric acid-coupled chloride channel produced by the repeated administration of pentylenetetrazol to rats. J. Neurochem. 55:1990;1216-1221.
13. Dantzer R. Behavioral effects of benzodiazepines. A review Biobehav. Rev. 1:1977;71-86.
14. De la Casa L.G., Ruiz G., Lubow R.E. Latent inhibition and recall/recognition of irrelevant stimuli as a function of preexposure duration in high and low psychotic-prone normals. Brit. J. Psychol. 84:1993;119-132.
15. Delini-Stula A., Berdahtordjman D. Benzodiazepines and GABA hypothesis of schizophrenia. J. Psychopharmacol. 9:1995;57-63.
16. Di Scala G., Meneses S., Brailowsky S. Chronic infusions of GABA into the medial frontal cortex of the rat induces a reversible delayed spatial alternation deficit. Behav. Brain Res. 40:1990;81-84.
17. Dorow R., Horowski R., Paschelke G., Amin M., Braestrup C. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet. 2:1983;98-99.
18. Dunn L.A., Scibilia R.J. Reaction time and pupil response measures show reduced latent inhibition in chronic schizophrenia. Soc. Neurosci. Abstr. 22:1996;239.
19. Estall L.B., Cooper S.J. Differential effects of benzodiazepine receptor ligands on isotonic saline and water consumption in water-deprived rats. Pharmacol. Biochem. Behav. 26:1987;247-252.
20. Feldon J., Weiner I. Abolition of the acquisition but not the expression of latent inhibition by chlordiazepoxide in rats. Pharmacol. Biochem. Behav. 32:1989;123-127.
21. Feldon J., Weiner I. An animal model of attention deficit. Boulton A.A., Baker G.B., Martin-Iverson M.T. Neuromethods, vol. 18. Animal models in psychiatry. 1991;313-361 Humana Press, Clifton, NJ.
22. Feldon J., Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J. Psychiatr. Res. 26:1992;345-366.
23. Gray J.A. Integrating schizophrenia. Schizophr. Bull. 24:1998;249-266.
24. Gray J.A., Joseph M.H., Hemsley D.R., Young A.M., Warburton E.C., Boulenguez P., Grigoryan G.A., Peters S.L., Rawlins J.N., Taib C.T. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition. Implications for schizophrenia Behav. Brain Res. 71:1995;19-31.
25. Gray N.S., Hemsley D.R., Gray J.A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol. Psychiatr. Brain Res. 1:1992;83-89.
26. Gray N.S., Pickering A.D., Hemsley D.R., Dawling S., Gray J.A. Abolition of latent inhibition by a single 5mg dose of d-amphetamine in man. Psychopharmacology (Berlin). 107:1992;425-430.
27. Gray N.S., Pilowsky L.S., Gray J.A., Kerwin R.W. Latent inhibition in drug naive schizophrenics. Relationship to duration of illness and dopamine D2 binding using SPET Schizophr. Res. 17:1995;95-107.
28. Haefely W. Benzodiazepine interactions with GABA receptors. Neurosci. Lett. 47:1984;201-206.
29. Haefely W., Martin J.R., Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. 11:1990;452-456.
30. Haefely W.E., Martin J.R., Richards J.G., Schoch P. The multiplicity of actions of benzodiazepine receptor ligands. Can. J. Psychiatry. 38:1993;102-108.
31. Hitchcock J.M., Lister S., Fischer T.R., Wettstein J.G. Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI. Effects of MDL 100,907, clozapine, risperidone and haloperidol Behav. Brain Res. 88:1997;43-49.
32. Holley L.A., Turchi J., Apple C., Sarter M. Dissociation between the attentional effects of infusions of a benzodiazepine receptor agonist and an inverse agonist into the basal forebrain. Psychopharmacology (Berlin). 120:1995;99-108.
33. Hunkeler W., Mohler H., Pieri L., Polc P., Bonetti E.P., Cumin R., Schaffner R., Haefely W. Selective antagonists of benzodiazepines. Nature. 290:1981;514-516.
34. Imperato A., Dazzi L., Obinu M., Gessa G., Biggio G. The benzodiazepine receptor antagonist flumazenil increases acetylcholine release in rat hippocampus. Brain Res. 647:1994;167-171.
35. Joseph M.H., Peters S.L., Gray J.A. Nicotine blocks latent inhibition in rats. Evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure Psychopharmacology (Berlin). 110:1993;187-192.
36. June H.L., Hughes R.W., Spurlock H.L., Lewis M.J. Ethanol self-administration in freely feeding and drinking rats. Effect of Ro15-4513 alone, and in combination with Ro15-1788 (flumazenil) Psychopharmacology (Berlin). 115:1994;332-339.
37. June H.L., Lewis M.J. Interactions of Ro15-4513, Ro15-1788 (flumazenil) and ethanol on measures of exploration and locomotion in rats. Psychopharmacology (Berlin). 116:1994;309-316.
38. Kalinowsky L.B. The convulsive therapies. Freedman A.M., Kaplan H.I., Sadock B.J. Comprehensive textbook of psychiatry, vol. 2. 1975;1969-1979 The Williams & Wilkins Co, Baltimore.
39. Killcross A.S., Stanhope K.J., Dourish C.T., Piras G. WAY100635 and latent inhibition in the rat. Selective effects at preexposure Behav. Brain Res. 88:1997;51-57.
40. Knapp J.R., Malatynska E., Yamamura H.I. From binding studies to the molecular biology of GABA receptors. Neurochem. Res. 15:1990;105-112.
41. Kumar R. Extinction of fear. II. Effects of chlordiazepoxide and chlorpromazine on fear and exploratory behaviour in rats. Psychopharmacologia. 19:1971;297-312.
42. Ljungberg T. Diazepam and decision making in the rat. negative evidence for reduced tolerance to reward delay Psychopharmacology (Berlin). 102:1990;117-121.
43. Ljungberg T., Lidfors L., Enquist M., Ungerstedt U. Impairment of decision making in rats by diazepam. Implication for the anticonflict effects of benzodiazepines Psychopharmacology (Berlin). 92:1987;416-423.
44. Lubow R.E. Latent inhibition. Psychol. Bull. 79:1973;398-407.
45. Lubow R.E. Latent inhibition and conditioned attention theory. 1989;Cambridge University Press, Cambridge.
46. Lubow R.E., Ingberg-Sachs Y., Zalstein-Orda N., Gewirtz J.C. Latent inhibition in low and high "psychotic-prone" normal subjects. Person. Indiv. Diff. 13:1992;563-572.
47. Lubow R.E., Moore A.U. Latent inhibition. The effects of non-reinforced pre-exposure to the conditioned stimulus J. Comp. Physiol. Psychol. 52:1959;415-419.
48. Lubow R.E., Weiner I., Feldon J. An animal model of attention. Spiegelstein M.Y., Levy A. Behavioral models and the analysis of drug action. 1982;89-107 Elsevier, Amsterdam.
49. Maickel R.P., Maloney G.J., Carter C.J. Effects of various depressant drugs on deprivation-induced water consumption. Neuropharmacology. 12:1973;777-782.
50. Mcdonald R.L., Barker J.L. Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mammalian neurones. Nature. 267:1977;720-721.
51. McGaughy J., Sarter M. Behavioral vigilance in rats. Task validation and effects of age, amphetamine and benzodiazepine receptor ligands Psychopharmacology (Berlin). 117:1995;340-357.
52. Meduna L., Friedman E. The convulsive-irritative therapy of psychoses. JAMA. 112:1939;501-509.
53. Meldrum B. GABA and acute psychoses. Psychol. Med. 12:1982;1-5.
54. Meldrum B. Pharmacology of GABA. Clin. Neuropharmacol. 5:1982;293-316.
55. Moore H., Sarter M., Bruno J.P. Bidirectional modulation of cortical acetylcholine efflux by infusion of benzodiazepine receptor ligands into the basal forebrain. Neurosci. Lett. 189:1995;31-34.
56. Pang K., Williams M.J., Egeth H., Olton D.S. Nucleus basalis magnocellularis and attention. Effects of muscimol infusions Behav. Neurosci. 107:1993;1031-1038.
57. Ramanjaneyulu R., Ticku M.K. Interactions of pentamethylenetetrazole and tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA receptor-ionophore complex. Eur. J. Pharmacol. 98:1984;337-345.
58. Ring H.A., Reynolds E.H. Vigabatrin and behaviour disturbance. Lancet. 335:1990;970.
59. Robbins T.W. The case for frontostriatal dysfunction in schizophrenia. Schizophr. Bull. 16:1990;391-402.
60. Rochford J., Sen A.P., Quirion R. Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. J. Pharmacol. Exp. Ther. 277:1996;1267-1275.
61. Rosenthal R., Rosnow R.L. Contrast analysis, focused comparisons in the analysis of variance. 1985;Cambridge University Press, Cambridge.
62. Solomon P.R., Crider A., Winkelman J.W., Turi A., Kamer R.M., Kaplan L.J. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity. Relationship to schizophrenic attention disorder Biol. Psychiatry. 16:1981;519-537.
63. Squires R.F., Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses. more support for a continuum hypothesis of "functional" psychosis Neurochem. Res. 16:1991;1099-1111.
64. Study R.E., Barker J.L. Diazepam and (-)-pentobarbital. Fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons Proc. Natl. Acad. Sci. USA. 78:1981;7180-7184.
65. Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophr. Res. 20:1996;91-103.
66. Tamminga C.A., Crayton J.W., Chase T.N. Muscimol. GABA agonist therapy in schizophrenia Am. J. Psychiatry. 135:1978;746-747.
67. Thornton J.C., Dawe S., Lee C., Capstick C., Corr P.J., Cotter P., Frangou S., Gray N.S., Russell M.A.H., Gray J.A. Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology (Berlin). 127:1996;164-173.
68. Vaitl D., Lipp O.V. Latent inhibition and automatic responses. A psychophysiological approach Behav. Brain Res. 88:1997;85-93.
69. Wafford K.A., Whiting P.J., Kemp J.A. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes. Mol. Pharmacol. 43:1993;240-244.
70. Warburton E.C., Joseph M.H., Feldon J., Weiner I., Gray J.A. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondanserton. implications for a possible antipsychotic action of ondanserton Psychopharmacology (Berlin). 114:1994;657-664.
71. Waser, P. G.: The pharmacology of amanita muscaria. In: Efron, D. H.; Homsted, B. N.; Kline, N. S., eds. Ethonopharmacologic search for psychoactive drugs: U.S. Public Health Service Publication; 1967.
72. Weiner I. Neural substrates of latent inhibition. the switching model Psychol. Bull. 108:1990;442-461.
73. Weiner I., Feldon J. The switching model of latent inhibition. an update of neural substrates Behav. Brain Res. 88:1997;11-25.
74. Weiner I., Feldon J., Bercovitz H. The abolition of the partial reinforcement extinction effect (PREE) by amphetamine. disruption of control by nonreinforcement Pharmacol. Biochem. Behav. 27:1987;205-210.
75. Weiner I., Lubow R.E., Feldon J. Chronic amphetamine and latent inhibition. Behav. Brain Res. 2:1981;285-286.
76. Weiner I., Lubow R.E., Feldon J. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berlin). 83:1984;194-199.
77. Weiner I., Lubow R.E., Feldon J. Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol. Biochem. Behav. 30:1988;871-878.
78. Weiner I., Shadach E., Tarrasch R., Kidron R., Feldon J. The latent inhibition model of schizophrenia. Further validation using the atypical neuroleptic, clozapine Biol. Psychiatry. 40:1996;834-843.